Antimicrobial resistance progression in the United Kingdom: A temporal comparison of Clostridioides difficile antimicrobial susceptibilities
- PMID: 34048922
- DOI: 10.1016/j.anaerobe.2021.102385
Antimicrobial resistance progression in the United Kingdom: A temporal comparison of Clostridioides difficile antimicrobial susceptibilities
Abstract
Objectives: Clostridioides difficile (CD) is widely reported as one of the most prevalent multi-drug resistant (MDR) organisms. Assessment of temporally disparate isolate collections can give valuable epidemiological data to further the understanding of antimicrobial resistance progression.
Methods: A collection of 75 CD isolates (1980-86) was characterised by PCR ribotyping, cell cytotoxicity assay and susceptibility testing with a panel of 16 antimicrobials and compared to a modern surveillance collection consisting of 416 UK isolates (2012-2016). Agar-incorporation was performed to ascertain susceptibility data for vancomycin, metronidazole, rifampicin, fidaxomicin, moxifloxacin, clindamycin, imipenem, chloramphenicol, tigecycline, linezolid, ciprofloxacin, piperacillin/tazobactam, ceftriaxone, amoxicillin, tetracycline and erythromycin. Genomes were obtained using Illumina HiSeq3000 sequencing and assembled using CLC Genomics Workbench. Resistance genes were identified using the Comprehensive Antibiotic Research Database's Resistance Gene Identifier and ResFinder3.0.
Results: Twenty-six known and one previously unobserved ribotype (RT) were detected. RT015 and RT020 dominated; 21.3% and 17.3%, respectively. Three moxifloxacin resistant (16-32 mg/L) RT027 isolates were recovered, pre-dating the earliest reports of this phenotype/genotype. Phenotypic resistance was observed to moxifloxacin (9.3% of isolates), ciprofloxacin (100%), erythromycin (17.3%), tetracycline (9.3%), linezolid and chloramphenicol (4.0%). Phenotypic comparisons with modern strains revealed increasing minimum inhibitory concentrations (MIC), with MIC50 elevations of one doubling-dilution for the majority of compounds, excluding clindamycin and imipenem. Moxifloxacin MIC90 comparisons revealed a two doubling-dilution increase between temporal isolate collections. Historical genomes revealed twenty different resistance determinants, including ermB (8.0% of isolates), tetM (9.3%), cfr (5.3%) and gyrA substitution Thr-82→Ile (9.3%). Seventeen isolates (22.7%) were resistant to ≥3 compounds (MDR), demonstrating ten different combinations. Intra-RT diversity was observed.
Conclusions: Antibiotic resistance in CD has increased since the early 1980s, across the majority of classes. Moxifloxacin resistance determinants may pre-date its introduction.
Keywords: Antimicrobial resistance; Antimicrobial susceptibility testing; C. difficile; Multi-drug resistance; Ribotype 027.
Copyright © 2021 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Antimicrobial susceptibilities, resistance mechanisms and molecular characteristics of toxigenic Clostridioides difficile isolates in a large teaching hospital in Chongqing, China.J Glob Antimicrob Resist. 2024 Sep;38:198-204. doi: 10.1016/j.jgar.2024.07.006. Epub 2024 Jul 22. J Glob Antimicrob Resist. 2024. PMID: 39048055
-
Reference Susceptibility Testing and Genomic Surveillance of Clostridioides difficile, United States, 2012-17.Clin Infect Dis. 2023 Mar 4;76(5):890-896. doi: 10.1093/cid/ciac817. Clin Infect Dis. 2023. PMID: 36208202 Free PMC article.
-
Five-year Pan-European, longitudinal surveillance of Clostridium difficile ribotype prevalence and antimicrobial resistance: the extended ClosER study.Eur J Clin Microbiol Infect Dis. 2020 Jan;39(1):169-177. doi: 10.1007/s10096-019-03708-7. Epub 2019 Dec 7. Eur J Clin Microbiol Infect Dis. 2020. PMID: 31811507 Free PMC article.
-
Antimicrobial resistance in Clostridioides (Clostridium) difficile derived from humans: a systematic review and meta-analysis.Antimicrob Resist Infect Control. 2020 Sep 25;9(1):158. doi: 10.1186/s13756-020-00815-5. Antimicrob Resist Infect Control. 2020. PMID: 32977835 Free PMC article.
-
A narrative review of Clostridioides difficile infection in China.Anaerobe. 2022 Apr;74:102540. doi: 10.1016/j.anaerobe.2022.102540. Epub 2022 Feb 24. Anaerobe. 2022. PMID: 35219837 Review.
Cited by
-
Genomic Epidemiology of Clostridioides difficile ST81 in Multiple Hospitals in China.Infect Drug Resist. 2024 Dec 11;17:5535-5544. doi: 10.2147/IDR.S492668. eCollection 2024. Infect Drug Resist. 2024. PMID: 39676847 Free PMC article.
-
Wolf in Sheep's Clothing: Clostridioides difficile Biofilm as a Reservoir for Recurrent Infections.Microorganisms. 2021 Sep 10;9(9):1922. doi: 10.3390/microorganisms9091922. Microorganisms. 2021. PMID: 34576818 Free PMC article. Review.
-
Broth Microdilution and Gradient Diffusion Strips vs. Reference Agar Dilution Method: First Evaluation for Clostridiales Species Antimicrobial Susceptibility Testing.Antibiotics (Basel). 2021 Aug 12;10(8):975. doi: 10.3390/antibiotics10080975. Antibiotics (Basel). 2021. PMID: 34439025 Free PMC article.
-
An Investigation into the Prevalence of Clostridioides difficile in Irish Pig Abattoirs and Pork Meat Products as a Potential Source of Human Infection.Antibiotics (Basel). 2025 Feb 4;14(2):151. doi: 10.3390/antibiotics14020151. Antibiotics (Basel). 2025. PMID: 40001395 Free PMC article.
-
Advances in Therapeutic Strategies for the Management of Clostridioides difficile Infection.J Clin Med. 2024 Feb 26;13(5):1331. doi: 10.3390/jcm13051331. J Clin Med. 2024. PMID: 38592194 Free PMC article. Review.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical